Biodesix (BDSX) EBITDA Yield: History & Chart

Biodesix, Inc.(BDSX)

Medical - Diagnostics & Research · Louisville, CO

$29.30+0.24 (+0.83%)

Delayed quote: Oct 6, 2026, 9:30 AM EDT

About Biodesix, Inc.

Biodesix, Inc. is a data-driven diagnostic solutions provider operating across the United States. Its primary focus includes a comprehensive suite of blood-based lung tests, marketed as the Nodify Lung Nodule Risk Assessment (which includes Nodify XL2 and Nodify CDT). These assessments enable clinicians to evaluate the risk of lung cancer in patients with suspicious nodules, aiding in the reclassification of malignancy risk and guiding appropriate treatment pathways. Beyond risk assessment, Biodesix offers additional lung cancer diagnostics such as GeneStrat ddPCR, which detects specific tumor mutations, and VeriStrat, which gauges the patient's immune system status. Both are crucial for establishing prognosis and informing treatment plans. Another offering is the GeneStrat NGS (Next-Generation Sequencing) test, a rapid, blood-based sequencing solution providing results within 72 hours. Through a partnership with Bio-Rad Laboratories, Inc., Biodesix also provides COVID-19 testing services under its Biodesix WorkSafe program, featuring the Bio-Rad SARS-CoV-2 ddPCR test and the Platelia SARS-CoV-2 Total Ab test, an antibody assay for detecting a B-cell immune response indicating recent or prior infection. Furthermore, the company extends its expertise to biopharmaceutical companies, offering diagnostic and clinical research services, alongside clinical trial testing. It also actively discovers, develops, and commercializes companion diagnostics. Originally incorporated as Elston Technologies, Inc. in 2005, Biodesix, Inc. maintains its headquarters in Boulder, Colorado.

Louisville, CO

334 employees

www.biodesix.com

Healthcare / Medical - Diagnostics & Research

Sector: Healthcare
Industry: Medical - Diagnostics & Research
CEO: Scott Hutton

View full financials

NAME	MARKET CAP	EBITDA YIELD	TTM	3Y	5Y
Biodesix, Inc. (BDSX)	$238.51M	N/A	N/A	N/A	N/A
High Tide Inc. (HITI)vs ›	$240.76M	7.72%	5.41%	5.10%	3.84%
Akebia Therapeutics, Inc. (AKBA)vs ›	$241.70M	N/A	6.75%	3.64%	3.64%
BioAge Labs Inc. (BIOA)vs ›	$242.46M	N/A	N/A	N/A	N/A
Lifecore Biomedical, Inc. (LFCR)vs ›	$244.19M	N/A	3.52%	3.58%	4.02%
Galectin Therapeutics Inc. (GALT)vs ›	$246.96M	N/A	N/A	N/A	N/A
Alector, Inc. (ALEC)vs ›	$230.93M	N/A	6.19%	6.19%	6.19%
Invivyd, Inc. (IVVD)vs ›	$251.06M	N/A	N/A	N/A	N/A
InflaRx N.V. (IFRX)vs ›	$248.92M	N/A	N/A	N/A	N/A
Greenwich LifeSciences, Inc. (GLSI)vs ›	$249.82M	N/A	N/A	N/A	N/A

NAME

MARKET CAP

EBITDA YIELD

TTM

Biodesix, Inc. (BDSX)

$238.51M

N/A

High Tide Inc. (HITI)vs ›

$240.76M

7.72%

5.41%

5.10%

3.84%

Akebia Therapeutics, Inc. (AKBA)vs ›

$241.70M

N/A

6.75%

3.64%

BioAge Labs Inc. (BIOA)vs ›

$242.46M

N/A

Lifecore Biomedical, Inc. (LFCR)vs ›

$244.19M

N/A

3.52%

3.58%

4.02%

Galectin Therapeutics Inc. (GALT)vs ›

$246.96M

N/A

Alector, Inc. (ALEC)vs ›

$230.93M

N/A

6.19%

Invivyd, Inc. (IVVD)vs ›

$251.06M

N/A

InflaRx N.V. (IFRX)vs ›

$248.92M

N/A

Greenwich LifeSciences, Inc. (GLSI)vs ›

$249.82M

N/A

EBITDA Yield Formula & Definition

EBITDA Yield = TTM EBITDA / Enterprise Value

EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.

EBITDA Yield: N/A

BDSX EBITDA Yield Metrics

BDSX Competitors' EBITDA Yield

EBITDA Yield Formula & Definition

Related Metrics